The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A–resistant cervical dystonia
Abstract
OBJECTIVE: To determine the safety and efficacy of botulinum toxin type B (BoNT/B) in patients with cervical dystonia (CD). BACKGROUND: BoNT/B is a form of chemodenervation therapy for the treatment of patients with CD. METHODS: The authors performed a 16-week, randomized, multicenter, double-blind, placebo-controlled trial of BoNT/B in patients with CD who continue to respond to botulinum toxin type A. Placebo, or 5,000 U or 10,000 U of BoNT/B was administered in two to four muscles involved clinically in CD. The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)-Total score at week 4 was the primary efficacy measure. Clinical assessments and adverse events were recorded for treatment day 1 and at weeks 2, 4, 8, 12, and 16. RESULTS: A total of 109 patients were enrolled randomly across all three treatment groups. The mean improvement in the TWSTRS-Total scores in each group at week 4 was 4.3 (placebo), 9.3 (5,000 U), and 11.7 (10,000 U). For the prospectively defined primary contrast (10,000 U versus placebo), highly significant differences were noted for the primary (TWSTRS-Total, baseline to week 4, p = 0.0004) and supportive secondary (Patient Global Assessment, baseline to week 4, p = 0.0001) outcome measures. Improvement in pain, disability, and severity of CD occurred for patients who were treated with BoNT/B when compared with placebo-treated patients. Overall, improvements associated with BoNT/B treatment were greatest for patients who received the 10,000-U dose. The duration of treatment effect for BoNT/B was 12 to 16 weeks for both doses. CONCLUSION: Botulinum toxin type B (NeuroBloc) is safe and efficacious at 5,000 U and 10,000 U for the management of patients with cervical dystonia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Schiavo, G. G., Benfenati, F., Poulain, B., Rossetto, O., de Laureto, P. P., DasGupta, B. R., & Montecucco, C. (1992) · Nature · doi:10.1038/359832a0 · Cited by 1,805
Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25
Blasi, J., Chapman, E. R., Link, E., Binz, T., Yamasaki, S., Camilli, P. D., Südhof, T. C., Niemann, H., & Jahn, R. (1993) · Nature · doi:10.1038/365160a0 · Cited by 1,220
DOUBLE-BLIND STUDY OF BOTULINUM TOXIN IN SPASMODIC TORTICOLLIS
Tsui, J. C., Jon Stoessl, A., Eisen, A., Calne, S., & Calne, D. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92070-2 · Cited by 810
Cervical dystonia: Clinical findings and associated movement disorders
Jankovic, J., Leder, S., Warner, D., & Schwartz, K. (1991) · Neurology · doi:10.1212/wnl.41.7.1088 · Cited by 424
Self-citationIdiopathic cervical dystonia: Clinical characteristics
Chan, J., Brin, M. F., & Fahn, S. (1991) · Movement Disorders · doi:10.1002/mds.870060206 · Cited by 417
Self-citationGreene, P., Kang, U., Fahn, S., Brin, M., Moskowitz, C., & Flaster, E. (1990) · Neurology · doi:10.1212/wnl.40.8.1213 · Cited by 306
Self-citationLew, M. F., Adornato, B. T., Duane, D. D., Dykstra, D. D., Factor, S. A., Massey, J. M., Brin, M. F., Jankovic, J., Rodnitzky, R. L., Singer, C., et al. (1997) · Neurology · doi:10.1212/wnl.49.3.701 · Cited by 233
Self-citationZuber, M., Sebald, M., Bathien, N., de Recondo, J., & Rondot, P. (1993) · Neurology · doi:10.1212/wnl.43.9.1715 · Cited by 195
Stages of regulated exocytosis
MARTIN, T. (1997) · Trends in Cell Biology · doi:10.1016/s0962-8924(97)01060-x · Cited by 155
Idiopathic Spasmodic Torticollis: Pathophysiology and Treatment
Gauthier, S. G. (1986) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100035964 · Cited by 140
Epidemiology of dystonia in Rochester, Minnesota.
Nutt, J. G., Muenter, M. D., Melton, L. J., Aronson, A., & Kurland, L. T. (1988) · PubMed · Cited by 116
Psychological functioning before and after treatment of torticollis with botulinum toxin.
Jahanshahi, M., & MARSDEN, C. D. (1992) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.229 · Cited by 62
Cited by
Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology
Pirazzini, M., Rossetto, O., Eleopra, R., & Montecucco, C. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.012658 · Cited by 768
Simpson, D. M., Blitzer, A., Brashear, A., Comella, C., Dubinsky, R., Hallett, M., Jankovic, J., Karp, B., Ludlow, C. L., Miyasaki, J. M., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000311389.26145.95 · Cited by 618
Self-citationBotulinum toxin in clinical practice
Jankovic, J. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.034702 · Cited by 408
Self-citationJankovic, J. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70574-9 · Cited by 332
Self-citationVolkmann, J., Mueller, J., Deuschl, G., Kühn, A. A., Krauss, J. K., Poewe, W., Timmermann, L., Falk, D., Kupsch, A., Kivi, A., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70143-7 · Cited by 330
Metadata
- Authors
- Brin, M. F., Lew, M. F., Adler, C. H., Comella, C. L., Factor, S. A., Jankovic, J., O’Brien, C., Murray, J. J., Wallace, J. D., Willmer–Hulme, A., & Koller, M.
- Venue
- Neurology
- Published
- 1999-10-22
- Volume
- 53
- Issue
- 7
- Pages
- 1431-1431
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2162700884
- Cited by
- 437
- References
- 15
- FWCI
- 17.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.